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Heparan Sulfate Proteoglycans Mediate the Angiogenic
Activity of the Vascular Endothelial Growth Factor
Receptor-2 Agonist Gremlin
Paola Chiodelli, Stefania Mitola, Cosetta Ravelli, Pasqua Oreste, Marco Rusnati, Marco Presta
Objective—Heparan sulfate proteoglycans (HSPGs) modulate the interaction of proangiogenic heparin-binding vascular
endothelial growth factors (VEGFs) with signaling VEGF receptor-2 (VEGFR2) and neuropilin coreceptors in
endothelial cells (ECs). The bone morphogenic protein antagonist gremlin is a proangiogenic ligand of VEGFR2,
distinct from canonical VEGFs. Here we investigated the role of HSPGs in VEGFR2 interaction, signaling, and
proangiogenic capacity of gremlin in ECs.
Methods and Results—Surface plasmon resonance demonstrated that gremlin binds heparin and heparan sulfate, but not
other glycosaminoglycans, via N-, 2-O, and 6-O-sulfated groups of the polysaccharide. Accordingly, gremlin binds
HSPGs of the EC surface and extracellular matrix. Gremlin/HSPG interaction is prevented by free heparin and heparan
sulfate digestion or undersulfation following EC treatment with heparinase II or sodium chlorate. However, at variance
with canonical heparin-binding VEGFs, gremlin does not interact with neuropilin-1 coreceptor. On the other hand,
HSPGs mediate VEGFR2 engagement and autophosphorylation, extracellular signaling-regulated kinase1/2 and p38
mitogen-activated protein kinase activation, and consequent proangiogenic responses of ECs to gremlin. On this basis,
we evaluated the gremlin-antagonist activity of a panel of chemically sulfated derivatives of the Escherichia coli K5
polysaccharide. The results demonstrate that the highly N,O-sulfated derivative K5-N,OS(H) binds gremlin with high
potency, thus inhibiting VEGFR2 interaction and angiogenic activity in vitro and in vivo.
Conclusion—HSPGs act as functional gremlin coreceptors in ECs, affecting its productive interaction with VEGFR2 and
angiogenic activity. This has allowed the identification of the biotechnological K5-N,OS(H) as a novel angiostatic
gremlin antagonist. (Arterioscler Thromb Vasc Biol. 2011;31:e116-e127.)
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Angiogenesis plays a key role in various physiologicaland pathological conditions, including embryonic devel-
opment, wound repair, inflammation, and tumor growth.1 Nu-
merous inducers of angiogenesis have been identified, including
the members of the vascular endothelial growth factor (VEGF)
family.2 Different isoforms of mammalian VEGFs interact with
tyrosine kinase VEGF receptors (VEGFRs) expressed on the
surface of endothelial cells (ECs)3 and with heparan sulfate (HS)
proteoglycan (HSPG) and neuropilin (NRP) coreceptors,4,5 thus
activating a proangiogenic response.
HSPGs consist of a core protein and of glycosaminoglycan
(GAG) chains represented by unbranched heparin-like poly-
saccharides. They are found in free forms, in the extracellular
matrix (ECM), or associated with the plasma membrane
where they regulate the function of a wide range of ligands.6,7
In particular, endothelial HSPGs modulate angiogenesis by
affecting bioavailability and interaction of heparin-binding
VEGFs with signaling VEGFRs and NRP coreceptors.8,9
Heparin/HS interaction with angiogenic growth factors de-
pends on the degree/distribution of sulfate groups and length
of the GAG chain, distinct oligosaccharide sequences medi-
ating its binding activity.10–12 Moreover, the study of the
biochemical bases of this interaction has been exploited to
design angiostatic heparin-like compounds, chemically mod-
ified heparins, and biotechnological heparins.13–16
Gremlin belongs to the CAN (Cerberus and Dan) family of
cystine-knot–secreted proteins.17,18 It binds various bone
morphogenic proteins (BMPs), thus preventing their interac-
tion with cell surface receptors.19 The capacity of gremlin to
bind BMPs and to inhibit their interaction with the cognate
transforming growth factor- (TGF-) family receptors is
thought to play a role in embryonic development of various
organ systems, such as bone, kidney, and lung.20–22 Also,
gremlin has been implicated in the pathogenesis of human
diseases, including pulmonary hypertension and idiopathic
pulmonary fibrosis23 and diabetic nephropathy.24 Moreover,
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gremlin is produced by human tumors25,26 and is expressed
by proangiogenic ECs in vitro and tumor endothelium in
vivo.27 Gremlin stimulates EC intracellular signaling and
migration in vitro, leading to a potent angiogenic response
in vivo.27,28 This is due to its capacity to bind and activate
VEGFR2, the main transducer of VEGF-mediated angio-
genic signals, in a BMP-independent manner.29 Thus,
gremlin acts as a VEGFR2 agonist distinct from VEGF
family members that may play paracrine/autocrine func-
tions in tumor neovascularization.
Scattered experimental evidence indicates that gremlin
may act as a heparin-binding angiogenic factor: gremlin binds
to heparin-Sepharose beads27; it associates to the surface of
producing cells30; and a heparin-binding domain has been
identified in sclerostin, a BMP antagonist structurally related
with gremlin.31,32 Here, we investigated the capacity of
gremlin to interact with heparin and cell-associated HSPGs
and the role of endothelial HSPGs in mediating gremlin-
dependent VEGFR2 activation and angiogenic activity. The
results demonstrate that gremlin binds heparin/HS. However,
at variance with canonical heparin-binding VEGFR2 ligands,
gremlin interacts with HSPGs but not with NRP-1 in ECs.
Nevertheless, cell surface HSPGs play a nonredundant role in
mediating the ability of gremlin to bind and activate VEGFR2
in endothelium, thus triggering an NRP-1-independent proan-
giogenic response. Accordingly, we have identified a chem-
ically modified, heparin-like derivative of the capsular Esch-




Recombinant gremlin, anti-gremlin antibody, and human recombi-
nant VEGF-A165 were from R&D Systems (Minneapolis, MN);
anti-phospho (P)-VEGFR2 antibody was from Cell Signaling Tech-
nology (Boston, MA); anti-tubulin antibody, heparinase II, phorbol
myristate acetate (PMA), and protease inhibitors were from Sigma-
Aldrich (St Louis, MO); anti-P-extracellular signaling–regulated
kinase (anti-P-ERK1/2), anti-VEGFR2, anti-ERK2, anti-p38, and
anti-P-p38 mitogen-activated protein kinase antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA); anti-actin antibody was
from Chemicon, Millipore (Billerica, MA); anti-focal adhesion
kinase (clone 2A7) was from Upstate, Millipore; sodium chlorate
was from BDH Laboratory Supplies (Pole, United Kingdom); type I
HS was from Opocrin (Corlo, Italy); and unmodified, fractionated
very-low–molecular weight (MW) heparins, chemically modified
heparins, and K5 polysaccharide derivatives were from Glycores
2000 (Milan, Italy). K5 derivatives were obtained by N-deacetyla-
tion/N-sulfation, O-sulfation, or both of a single batch of E. coli K5
polysaccharide (see Leali et al33 for a description of these com-
pounds). Dermatan sulfate, chondroitin-4-sulfate, chondroitin-6-
sulfate, and hyaluronic acid were obtained from Dr M. Del Rosso,
University of Florence, Italy (see Rusnati et al34 for a description of
these GAGs). Tinzaparin sodium was from LEO Pharmaceutical
Products, Ltd (Ballerup, Denmark). The HS-specific monoclonal
antibody 10E435 was kindly provided by G. David (Leuven Univer-
sity, Leuven, Belgium).
Surface Plasmon Resonance Analysis
Surface plasmon resonance (SPR) measurements were performed on
a BIAcore X instrument (GE Healthcare). For the study of gremlin/
heparin interaction, heparin was immobilized onto a CM3 sensor
chip (GE Healthcare) as described.36 A streptavidin-coated sensor
chip was used as reference and for blank subtraction. Increasing
concentrations of gremlin in 10 mmol/L HEPES buffer (HBS-EP),
pH 7.4, containing 150 mmol/L NaCl, 3 mmol/L EDTA, and 0.005%
surfactant P20 (HBS-EP) (GE Healthcare) were injected over the
heparin-coated or streptavidin surfaces for 4 minutes and then
washed until dissociation was observed. After each run, the sensor
chip was regenerated by injection of HBS-EP containing 2.0 mol/L
NaCl.
In all experiments, association and dissociation rates (kon and koff,
respectively) were obtained by fitting the raw sensorgrams with the
1:1 Langmuir binding model using the Biaevaluation software
(BIAcore). Equilibrium affinity constants (expressed as dissociation
constant, kd) were either derived from the kinetic parameters
(kdkoff/kon) or determined from Scatchard plot analysis of the
equilibrium binding data.
Cell Cultures
Human umbilical vein endothelial (HUVE) cells were used at early
passages (passages I–IV) and grown on plastic surface coated with
porcine gelatin (Sigma-Aldrich) in M199 medium (Invitrogen, Carls-
bad, CA) supplemented with 20% fetal calf serum (FCS) (Invitro-
gen), EC growth factor (100 g/mL) (Sigma-Aldrich), and porcine
heparin (100 g/mL, Sigma-Aldrich). Fetal bovine aortic endothelial
GM 7373 cells37 were grown in Dulbecco’s modified Eagle medium
(Invitrogen) containing 10% FCS, vitamins, and essential and
nonessential amino acids. These cells were transfected according to
standard protocols with a pcDNA3.1 expression vector harboring the
mouse VEGFR2 cDNA (provided by G. Breier, Max Planck Insti-
tute, Bad Nauhein, Germany) to generate stable GM7373-VEGFR2
transfectants. Wild-type Chinese hamster ovary cells (CHO)-K1
cells and GAG-deficient A745 CHO cells38 were kindly provided by
J.D. Esko (University of California, La Jolla, CA) and grown in
Ham’s F-12 medium supplemented with 10% FCS.
To inhibit the sulfation of cell-associated HS chains, GM7373 and
HUVE cells were grown for 48 hours in presence of sodium
chlorate (50 and 30 mmol/L, respectively).39 Alternatively, cells
were incubated for 2 hours at 37°C with heparinase II (15 mU/mL
in phosphate-buffered saline [PBS], Sigma-Aldrich) before
experimentation.
Human pancreatic carcinoma (PANC-1) cells were grown in
Dulbecco’s modified Eagle medium containing 10% FCS, vitamins,
and essential and nonessential amino acids. Gremlin-overexpressing
PANC-1 cells (PANC-1-gremlin cells) were generated by infection
with the pRRLsin.cPPT.PGK lentiviral vector (kindly provided by L.
Naldini, San Raffaele Institute, Milan, Italy) harboring the rat
gremlin cDNA.40 Green fluorescent protein (GFP)–overexpressing
PANC-1 cells (PANC-1-GFP cells) were generated with the same
procedures and used as a negative control. PANC-1-GFP and
PANC-1-gremlin cells were grown for 48 hours in serum-free
Dulbecco’s modified Eagle medium and their conditioned media
were analyzed for gremlin content by Western blotting and for the
capacity to induce VEGFR2 phosphorylation in HUVE cells.
Gremlin/Cell-Associated HSPG Binding Assays
CHO-K1 cells; GAG-deficient A745 CHO-K1 cells; and untreated,
chlorate-treated, or heparinase II–treated GM7373 cells were incu-
bated with gremlin (100 ng/mL) for 2 hours at 4°C in serum-free
medium in the absence or in the presence of the indicated competitor.
Then, cells were washed twice with PBS or with PBS plus 1.5 mol/L
NaCl to remove gremlin bound to HSPGs.41 Next, immunofluores-
cence analysis was performed using an anti-gremlin antibody fol-
lowed by Alexa Fluor 488 anti-goat IgG (Invitrogen), and cells were
photographed using a Zeiss Axiovert 200M epifluorescence micro-
scope equipped with a Plan-Apochromat 63/1.4 NA oil objective.
Alternatively, HSPG-bound gremlin was collected in SDS-PAGE
sample buffer and analyzed with anti-gremlin antibody by Western
blotting.
In a parallel set of experiments, cell-free subendothelial ECM
preparations were obtained by incubating GM7373 cells for 3
minutes at room temperature with 0.5% Triton X plus 0.00375%
NH3 in PBS.42 Next, cell-free ECM preparations were incubated
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with gremlin and analyzed for HSPG-bound gremlin as described
above.
VEGFR2 Cross-Linking Assay
Confluent GM7373-VEGFR2 cells were incubated for 2 hours at
4°C with gremlin dissolved in PBS containing the bis(sulfosucci-
namide) suberate cross-linking reagent (BS3, Pierce). Then, cells
were lysed in 50 mmol/L Tris-HCl buffer (pH 7.4) containing
150 mmol/L NaCl, 1% Triton X-100, 1.0 mmol/L Na3VO4, and
protease inhibitors. Lysates were immunoprecipitated and separated
by SDS-PAGE followed by Western blotting with anti-gremlin or
anti-VEGFR2 antibodies.
ELISA
Ninety-six-well plates were coated for 16 hours at room temperature
with the extracellular domain of soluble VEGFR2D1–7 (soluble
VEGFR2, Calbiochem) or rat NRP-1 receptor (R&D Systems) in
PBS followed by a 3-hour blocking step with 1% bovine serum
albumin. Next, gremlin or VEGF-A165 (in PBS containing 0.1%
bovine serum albumin, 5 mmol/L EDTA, 0.004% Tween 20
[PBET]) were sequentially incubated for 1 hour at 37°C and for 1
hour at room temperature. For competitive ELISA, gremlin was
added in presence of K5 derivates. Then, wells were further
incubated for 1 hour at 37°C and for an additional 1 hour at room
temperature with an anti-gremlin antibody or anti-VEGF antibody
(R&D Systems), both at 100 ng/mL in PBET. Finally, wells were
incubated for 1 hour at room temperature with a secondary anti-goat
or anti-mouse horseradish peroxidase–conjugated antibody (Santa
Cruz Biotechnology).
VEGFR2/NRP-1 Coimmunoprecipitation Analysis
Confluent HUVE cells were made quiescent by a 16-hour starvation
in M199 medium containing 5% FCS. Cells were then stimulated
with gremlin (50 ng/mL) or VEGF-A165 (30 ng/mL) and lysed in
50 mmol/L Tris-HCl buffer, pH 7.4, containing 150 mmol/L NaCl,
1% Triton X-100, 10% glycerol, and a protease/phosphatase inhib-
itors mix (Sigma-Aldrich). After centrifugation (15 minutes,
10 000g), supernatants were precleared by 1 hour of incubation with
protein A–Sepharose (Sigma-Aldrich). Samples (1 mg of proteins)
were incubated overnight at 4°C with rabbit polyclonal anti-
VEGFR2 antibody (Santa Cruz Biotechnology), and immune com-
plexes were recovered on protein A–Sepharose. Immunoprecipitates
were washed 4 times with lysis buffer, twice with the same buffer
without Triton X-100 and once with TBS. Proteins were solubilized
under reducing conditions, separated by SDS-PAGE (8%), and
analyzed by Western blotting with anti-NRP-1 and anti-P-VEGFR2
(Tyr1175) antibodies. Uniform immunoprecipitation was confirmed
using an anti-VEGFR2 antibody.
Immunofluorescence Analysis
Cells were seeded on glass coverslips in M199 medium containing
2% FCS. Cells were treated with gremlin (100 ng/mL) for 10
minutes at 37°C, fixed in 3% paraformaldehyde/2% sucrose in PBS,
permeabilized with 0.5% Triton X-100, and saturated with goat
serum in PBS. Then, cells were incubated with an anti-P-VEGFR2
antibody followed by Alexa Fluor 488 anti-rabbit IgG (Invitrogen).
Cells were analyzed using a Zeiss Axiovert 200M epifluorescence
microscope or a LSM510 Meta confocal microscope equipped with
a Plan-Apochromat 63/1.4 NA oil objective.
Western Blot Analysis
Confluent HUVE cells were made quiescent by a 16 hours-starvation
in M199 medium containing 5% FCS. After stimulation with gremlin
(100 ng/mL), cells were lysed in 50 mmol/L Tris–HCl buffer, pH
7.4, containing 150 mmol/L NaCl, 1% Triton X-100, 0.1% Brij and
a protease/phosphatase inhibitors mix (Sigma-Aldrich) and 50 to 100
g aliquots of the cell extracts were analyzed by 6% to 8%
SDS-PAGE followed by Western blotting with anti-P-VEGFR2,
P-ERK1/2 or P-p38 mitogen-activated protein kinase antibodies. In
all the experiments, uniform loading of the gels was confirmed using
anti-focal adhesion kinase, VEGFR2, ERK2 or p38 antibodies.
Chemotaxis Assay
HUVE cells (1.0106 cells/mL) were seeded in M199 medium
containing 2% FCS in the upper compartment of a Boyden chamber
containing gelatin-coated polyvinylpyrrolidone-free polycarbonate
filters (8 m pore size, Costar, Cambridge, MA). Gremlin (10
ng/mL) or PMA (100 ng/mL) in M199 containing 2% FCS was
placed in the lower compartment. A 2% FCS medium was used as
negative control. After 4 hours of incubation at 37°C, cells that had
migrated to the lower side of the filter were stained with Diff-Quik
(Dade-Behring, Milan, Italy). Five random fields were counted for
each triplicate sample.
Cell Motility Assay
Cell motility was assessed by time-lapse videomicroscopy. Cells
were seeded at 150 cells/cm2 in 24-well plates for 2 hours and then
stimulated with gremlin (100 ng/mL). Constant temperature (37°C)
and pCO2 (5%) were maintained throughout the experimental period
by means of an heatable stage and climate chamber. Cells were
observed under an inverted photomicroscope (Zeiss Axiovert 200M),
and phase-contrast snap photographs (1 frame every 8 minutes) were
digitally recorded for 360 minutes. Cell paths (25–30 cells per
experimental point) were generated from centroid positions and
migration parameters were analyzed with the Chemotaxis and
Migration tool of ImageJ software (http://rsbweb.nih.gov/ij).
EC Sprouting Assay
Sprouting of HUVE cell aggregates embedded in fibrin gel was
analyzed as described.27 Briefly, spheroids were prepared in 20%
methylcellulose medium, embedded in fibrin gel, and stimulated
with gremlin (50 ng/mL) in the absence or in the presence of K5
derivatives. Formation of radially growing cell sprouts was observed
during the next 24 hours and photographed at a 200 magnification
using an Axiovert 200M microscope equipped with a 20 objective
(LD A Plan 20/0.30PH1, Zeiss).
Chick Embryo Chorioallantoic Membrane Assay
Alginate beads (5 L) containing vehicle or gremlin (100 ng/bead)
were placed on the chorioallantoic membrane of fertilized white
Leghorn chicken eggs at day 11 of incubation28 in the absence or in
the presence of K5 or K5-N,OS(H) (both at 1 g/bead). After 72
hours, newly formed blood vessels converging toward the implant
were counted at a 5 magnification using a STEMI SR stereomi-
croscope equipped with an objective f of 100 mm with adapter ring
475070 (Zeiss).
Human Artery Ring Assay
One-millimeter human umbilical artery rings were embedded in
fibrin gel28 in the presence of the conditioned medium from
PANC-1-GFP or PANC-1-gremlin cells in the absence or in the
presence of 100 ng/mL K5 derivatives. After 6 days, EC sprouts,
morphologically distinguishable from scattering fibroblasts/smooth
muscle cells, were counted. Then, rings were photographed at a
100 magnification using an Axiovert 200M microscope equipped
with a 20 objective (LD A PLAN 20X/0.30PH1, Zeiss).
Statistical Analysis
Data were expressed as meanSD. The analysis was performed
using ANOVA models with probability values correction for multi-
ple comparisons.43
Results
Characterization of Gremlin/Heparin Interaction
Real-time SPR analysis was exploited to characterize grem-
lin/heparin interaction. Increasing concentrations of gremlin
were injected over a streptavidin-activated BIAcore sensor
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chip coated with biotinylated heparin (Figure 1A). Analysis
of kinetic parameters (kon and koff1.86105 [mol/L]1 per
second1 and 3.66103 per second1, respectively), and
Scatchard plot analysis of steady-state SPR (data not shown)
demonstrates that gremlin/heparin interaction occurs with
high affinity (Kd20 nmol/L).
The capacity of different GAGs to inhibit the binding of
gremlin to immobilized heparin was then evaluated in a SPR
competition assay (Figure 1B). Free heparin and HS pre-
vented the binding of gremlin to immobilized heparin with
ID50 values of 0.12 and 0.7 g/mL, respectively (data not
shown), whereas dermatan sulfate, chondroitin-4-sulfate,
chondroitin-6-sulfate, and hyaluronic acid were ineffective.
Thus, GAG/gremlin interaction depends, at least in part, on
differences in GAG structure and degree of sulfation. On this
basis, selectively desulfated heparins were evaluated in the
SPR competition assay (Figure 1C). No competition was
exerted by totally O-desulfated heparin, whereas 2-O-
desulfated, 6-O-desulfated, and N-desulfated/N-acetylated
heparins show a significant reduction in the capacity to
inhibit the binding of gremlin to the heparin-coated sensor
chip (ID500.6, 0.6, and 0.9 g/mL, respectively) compared
with unmodified heparin (ID500.12 g/mL). Taken to-
gether, the data indicate that at least some 2-O-, 6-O-, and
N-sulfate groups must be organized on the same heparin
chain to allow an optimal interaction with gremlin.
Also, the influence of the length of the heparin chain on its
binding activity was investigated by using tinzaparin, a thera-
peutic low-MW heparin whose MW ranges between 5.5 and 7.5
kDa,44 and 3 different very-low-MW heparins (average MWs of
4.0, 3.0, and 2.1 kDa, respectively). On a molar basis, tinzaparin
binds gremlin with an affinity that is similar to unmodified
heparin, whereas the capacity of very-low-MW heparins to bind
gremlin is progressively reduced as a function of size, with
2.1-kDa heparin showing the weakest activity (Figure 1D).
Gremlin Binds EC-Associated HSPGs
We then evaluated the capacity of gremlin to interact with
cell-associated HSPGs. In a first set of experiments, HSPG-
bearing CHO-K1 cells and GAG-deficient A745 CHO-K1 cell
mutants45 were incubated with gremlin at 4°C to prevent the
internalization of the protein and decorated with anti-gremlin
antibody. Confocal microscopy (Figure 2) and immunofluores-
cence analysis (Figure 3A) demonstrated the capacity of gremlin
Figure 1. Surface plasmon resonance (SPR) analysis of gremlin/
heparin interaction. A, Sensorgram overlay showing the binding
of increasing amounts of gremlin (1.25, 2.5, 5.0, 10.0, 20.0,
40.0, and 80.0 nmol/L) to a heparin-coated BIAcore sensor chip.
The response (in resonance units [RU]) was recorded as a func-
tion of time. B to D, SPR competitive studies performed by
injecting gremlin (20 nmol/L) on the heparin surface in the pres-
ence of different glycosaminoglycans (all at 1.0 g/mL) (B);
increasing concentrations of unmodified heparin (Œ),
N-desulfated/N-acetylated heparin (E), 6-O-desulfated heparin
(f), 2-O-desulfated heparin (), and totally O-desulfated heparin
(F) (C); or increasing concentrations of unmodified heparin (Œ),
very-low–molecular weight (MW) 4.0-kDa heparin (f), 3.0-kDa
heparin (), 2.1-kDa heparin (F), or tinzaparin (E) (D). The
response (in RU) was recorded at the end of the injection. Each
point is the meanSD of 2 or 3 independent experiments. HS
indicates heparan sulfate; DS, dermatan sulfate; C-4-S,
chondroitin-4-sulfate; C-6-S, chondroitin-6-sulfate; HA, hyal-
uronic acid.
Figure 2. Confocal analysis of gremlin binding to cell-surface
heparan sulfate proteoglycans (HSPGs). CHO-K1 cells (A) and
glycosaminoglycan-deficient A745 CHO-K1 cells (B) were incu-
bated with gremlin (100 ng/mL) for 2 hours at 4°C. At the end of
incubation, nonpermeabilized cells were decorated with anti-
gremlin antibody (in green) and 4,6-diamidino-2-phenylindole (in
blue). z-Stack sections and orthogonal z reconstitution were an-
alyzed by confocal microscopy.
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to bind the surface of CHO-K1 cells but not of GAG-deficient
A745 CHO-K1 cells. The binding of gremlin to CHO-K1 cell
surface was inhibited by free heparin or HS, whereas hyaluronic
acid was ineffective. Also, in keeping with a postulated HSPG
interaction, a 1.5 mol/L NaCl wash detached gremlin bound to
the CHO-K1 cell surface. Similar results were obtained when
cell-surface bound gremlin was analyzed by Western blotting of
the cell monolayers (Figure 3B).
We then evaluated the capacity of gremlin to bind EC-
associated HSPGs. In keeping with the data obtained with
CHO-K1 cells, immunofluorescence analysis revealed that
gremlin binds the surface of bovine aortic endothelial
GM7373 cells and that the binding is competed by heparin or
abrogated by a 1.5 mol/L NaCl wash (data not shown).
Accordingly, digestion of cell-associated HSPGs by hepari-
nase II or inhibition of the sulfation of the HS chains by
pretreatment of ECs with sodium chlorate both prevented the
binding of gremlin to the EC surface (Figure 3C). Similar
results were obtained with HUVE cells (see below).
Finally, we analyzed the capacity of gremlin to bind
HSPGs associated with the cell-free subendothelial ECM
deposited by GM7373 cells (Figure 3C). Also in this case,
binding of gremlin to subendothelial ECM was prevented by
digestion with heparinase II, pretreatment of ECs with chlo-
rate before ECM isolation, or coincubation with heparin.
Again, a 1.5 mol/L NaCl wash was able to remove gremlin
from subendothelial ECM-associated HSPGs.
HSPGs Are Required for VEGFR2 Binding and
Activation by Gremlin
Previous observations had implicated HSPGs in the interac-
tion of heparin-binding VEGF isoforms with tyrosine kinase-
Figure 3. Binding of gremlin to cell-associated heparan sulfate proteoglycans (HSPGs). A, CHO-K1 cells and glycosaminoglycan-
deficient A745 CHO-K1 cell mutants were incubated for 2 hours at 4°C with gremlin alone (100 ng/mL) or in the presence of heparin,
heparan sulfate (HS), or hyaluronic acid (HA) (all at 1.0 g/mL). Then, nonpermeabilized cells were washed with PBS or with PBS plus
1.5 mol/L NaCl (salt wash) and decorated with an anti-gremlin antibody (in green) followed by nuclear counterstaining with 4,6-
diamidino-2-phenylindole (in blue). B, CHO-K1 and A745 CHO-K1 cells were incubated with gremlin as in A, and cell lysates were ana-
lyzed by Western blot (WB) with an anti-gremlin antibody. C, Subendothelial extracellular matrices (ECMs) were prepared from
untreated or chlorate- or heparinase II–treated GM7373 cell monolayers. Then, living cells or their ECMs were incubated for 2 hours at
4°C with gremlin (100 ng/mL) in the absence or in the presence of heparin (1.0 g/mL), washed with PBS or with PBS plus 1.5 mol/L
NaCl (salt wash) and analyzed by Western blotting with an anti-gremlin antibody. Uniform loading of the samples was confirmed by
Western blotting with an anti-actin antibody. The data are representative of 2 or 3 independent experiments that gave similar results.
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VEGFR2 and NRP-1 coreceptor in ECs.4,46 However, at
variance with the prototypic heparin-binding VEGFR2 ligand
VEGF-A165 and similar to VEGF-A121 that lacks the
heparin/NRP-1 binding domain,4,47 gremlin does not induce
VEGFR2/NRP-1 complex formation when administered to
HUVE cells (Figure 4A), thus indicating that HSPG interac-
tion is not per se sufficient to drive NRP-1 engagement. Also,
gremlin does not directly bind recombinant NRP-1 produced
in mammalian cells in ELISA (Figure 4B) or NRP-1 ex-
pressed on HUVE cells in cross-linking experiments (data not
shown). Thus, gremlin appears to differ from canonical
heparin-binding VEGFs in the ability to co-opt VEGFR2
coreceptors.
On this basis, we investigated whether HSPG corecep-
tors play any role in mediating a productive interaction of
gremlin with VEGFR2.29 In a first set of experiments, we
exploited VEGFR2-overexpressing endothelial GM7373
cells (GM7373-VEGFR2 cells) that express HSPGs and high
levels of VEGFR2 on their cell surface (Figure 5). These cells
were incubated at 4°C with gremlin in the presence of the
bis(sulfosuccinamide)suberate cross-linking reagent BS3. Af-
ter incubation, cell lysates were immunoprecipitated with
anti-gremlin antibodies, and immunocomplexes were ana-
lyzed by Western blotting with anti-VEGFR2 antibodies.
When cross-linked to the GM7373-VEGFR2 cell surface,
gremlin forms a 250-kDa VEGFR2 complex whose forma-
tion is abrogated when the cross-linking reaction was per-
formed in chlorate-treated cells (Figure 6A). Accordingly,
chlorate pretreatment abolished the capacity of gremlin to
induce VEGFR2 autophosphorylation in HUVE cells, as
shown by immunostaining of intact cells and Western blot-
ting of the cell extracts using an anti-P-VEGFR2 antibody
(Figure 6B and 6C). Also, the capacity of gremlin to induce
ERK1/2 and p38 mitogen-activated protein kinase phosphor-
ylation was hampered in chlorate-pretreated HUVE cells
(Figure 6C). Similar results were obtained when HUVE cells
were incubated with heparinase II before gremlin stimulation
(data not shown). Also, addition of increasing concentrations
of unmodified heparin to the cell culture medium restored the
capacity of gremlin to induce VEGFR2 autophosphorylation
in chlorate-pretreated HUVE cells (Figure 6D). It must be
pointed out that even though chlorate pretreatment prevented
the binding of gremlin to the HUVE cell surface (Figure 7A),
it did not affect cell viability and the capacity of the protein
kinase C activator PMA to induce ERK1/2 phosphorylation in
these cells (Figure 7B and 7C), confirming the specificity of
the effect. Taken together, these observations demonstrate
that HSPGs are required for a productive interaction of
gremlin with VEGFR2.
HSPGs Mediate the Angiogenic Activity
of Gremlin
Stimulation of EC motility is part of the VEGFR2-dependent
angiogenic program activated by gremlin.27,29 To assess the
Figure 4. Gremlin does not interact with neuropilin-1 (NRP-1). A,
Quiescent human umbilical vein endothelial (HUVE) cells were
incubated for 15 minutes at room temperature in the absence
(control) or in the presence of vascular endothelial growth factor
(VEGF)–A165 (30 ng/mL) or gremlin (50 ng/mL), lysed, and
immunoprecipitated (IP) with anti-VEGF receptor-2 (VEGFR2)
antibody, and immunocomplexes were probed in a Western blot
(WB) with anti-P-VEGFR2 or anti-NRP-1 antibodies. Uniform
loading of the gel was confirmed by WB with anti-VEGFR2 anti-
body. The P-VEGFR2/VEGFR2 and NRP-1/VEGFR2 ratios are
shown at the bottom of the corresponding blots, as calculated
by densitometric measurement of the bands. B, 96-well plates
coated with 2 g/mL NRP-1 were incubated with increasing
concentrations of VEGF-A165 or gremlin. Then, the capacity of
VEGF-A165 or gremlin to bind to the immobilized receptor was
assessed by incubation with anti-VEGF-Ala or anti-gremlin anti-
bodies, respectively.
Figure 5. Heparan sulfate proteoglycan (HSPG) and vascular
endothelial growth factor receptor-2 (VEGFR2) expression by
endothelial GM7373-VEGFR2 cells. Parental and VEGFR2-
overexpressing endothelial GM7373 cells were analyzed for
VEGFR2 expression by Western blotting (WB) of the cell lysates
(A) and by immunofluorescence analysis with an anti-VEGFR2
antibody (B, a and b). Cells were also decorated with the anti-
heparan sulfate monoclonal antibody 10E4 (B, c and d). In B,
cells were also counterstained with 4,6-diamidino-2-
phenylindole (in cyan).
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role of HSPGs in mediating the angiogenic activity of
gremlin, chlorate-pretreated HUVE cells were tested in a
Boyden chamber assay for their capacity to migrate through
a gelatin-coated filter in response to gremlin. Despite a
similar capacity to adhere to immobilized gelatin (Figure 7D)
and to migrate in response to PMA (Figure 8A), chlorate-
pretreated HUVE cells displayed a dramatic reduction in their
chemotactic response to gremlin compared with control cells
(Figure 8A). Again, HSPG digestion following heparinase II
incubation mimicked the effect of chlorate, thus abolishing
the chemotactic activity of gremlin in HUVE cells (data not
shown). In keeping with these observations, chlorate pretreat-
ment abolished the motogenic response of HUVE cells to
gremlin as assessed by time-lapse microscopy, without af-
fecting EC motility induced by PMA (Figure 8B). Moreover,
as observed for gremlin-induced VEGFR2 autophosphoryla-
tion (see Figure 6D), addition of heparin to chlorate-treated
cells restored their motogenic response to gremlin stimulation
(Figure 8C).
To confirm the role of HSPGs in mediating EC activation
by gremlin, spheroids of chlorate or heparinase II–treated
HUVE cells were embedded in a 3-dimensional fibrin gel and
stimulated with gremlin.29 As shown in Figure 8D and 8E,
HSPG digestion or undersulfation caused a significant reduc-
tion in the number and length of EC sprouts induced by
gremlin.
Heparin-Like K5 Derivatives as
Gremlin Antagonists
The capsular E. coli K5 polysaccharide has the same structure
as the heparin precursor N-acetyl heparosan.16 K5 derivatives
can be generated by chemical sulfation in the N- or
O-position, leading to heparin-like molecules with defined
sulfation patterns48 and able to hamper the angiogenic activity
of the heparin-binding fibroblast growth factor-2.33
To assess their ability to act as gremlin antagonists, a panel
of selectively sulfated K5 derivatives (including the
N-sulfated derivative K5-NS; the O-sulfated derivatives with
low and high degrees of sulfation, K5-OS(L) and K5-OS(H);
and the N,O-sulfated derivatives with low and high degrees of
sulfation, K5-N,OS(L) and K5-N,OS(H))33 were evaluated
for their capacity to prevent gremlin/heparin interaction in a
SPR competition assay. As shown in Figure 9A, K5-N,OS(H)
and K5-N,OS(L) competed for the binding of gremlin to
immobilized heparin with high potency (ID50 of 0.05 and 0.2
Figure 6. Endothelial heparan sulfate proteoglycans (HSPGs)
mediate vascular endothelial growth factor receptor-2 (VEGFR2)/
gremlin interaction and signaling. A, Control and chlorate-
treated GM7373-VEGFR2 cells were incubated for 2 hours at
4°C with gremlin (100 ng/mL). After a further incubation with the
cross-linking reagent BS3, cell lysates (1.0 mg) were immuno-
precipitated with anti-gremlin antibody and probed with the
same antibody or with an anti-VEGFR2 antibody in a Western
blot. B, Serum-starved control and chlorate-treated human
umbilical vein endothelial (HUVE) cells were stimulated for 10
minutes at 37°C with gremlin (100 ng/mL), decorated with
anti-VEGFR2 or anti-P-VEGFR2 antibodies (in green) followed by
nuclear counterstaining with 4,6-diamidino-2-phenylindole (in
blue), and observed under a confocal microscope. C, Serum-
starved control and chlorate-treated HUVE cells were stimulated
for 10 minutes at 37°C with gremlin (100 ng/mL) and cell lysates
(50 g) were analyzed by Western blotting with anti-P-VEGFR2,
anti-P-extracellular signaling–regulated kinase (P-ERK1/2) or anti-
P-p38 mitogen-activated protein kinase (MAPK) antibodies
(p38). D, Serum-starved chlorate-treated HUVE cells were incu-
bated for 10 minutes at 37°C with gremlin (100 ng/mL) and
increasing concentrations of heparin. Then, cell lysates (50 g)
were analyzed by Western blotting with anti-P-VEGFR2 anti-
body. Uniform loading of the gels was confirmed by incubation
of the membranes with antibodies directed against the unphos-
phorylated form of the antigen. The data are representative of 2
or 3 independent experiments that gave similar results.
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g/mL, respectively), whereas K5-OS(H) and K5-OS(L)
were less effective (ID50 of 0.5 and 1.0 g/mL, respectively).
K5-NS and unmodified K5 did not exert a significant
competition.
Then, the most active derivative K5-N,OS(H) was tested
for the capacity to affect the angiogenic activity exerted by
gremlin in vitro and in vivo. As shown in Figure 9B and 9C,
K5-N,OS(H) inhibits the binding of gremlin to the extracel-
lular domain of VEGFR2 in a competitive ELISA and its
ability to stimulate the sprouting of HUVE cell aggregates in
fibrin gel. Also, K5-N,OS(H) exerts a potent inhibitory
activity on blood vessel formation triggered by gremlin
delivered on the top of the chick embryo chorioallantoic
membrane via an alginate pellet implant (Figure 9D and 9E).
Accordingly, K5-N,OS(H) inhibits the angiogenic activity
exerted by gremlin in a tumor-driven ex vivo angiogenesis
assay in which fibrin-embedded human umbilical cord artery
rings28 are grown in the presence of the conditioned medium
from gremlin-overexpressing human pancreatic carcinoma
PANC-1 cells (Figure 10A and 10B). As shown in Figure
10C and 10D, PANC-1-gremlin cells, but not control PANC-
1-GFP cells, induce a dramatic increase in the formation of
EC sprouts from human artery rings that is significantly
inhibited by K5-N,OS(H). When tested under the same
experimental conditions, unmodified K5 was ineffective in all
these assays.
Figure 7. Characterization of chlorate-treated human umbilical vein endothelial (HUVE) cells. A, HUVE cell monolayers were left
untreated or treated with chlorate. Then, cells were incubated for 2 hours at 4°C with gremlin (100 ng/mL) in the absence or in the
presence of heparin (1 g/mL), washed with PBS or with PBS plus 1.5 mol/L NaCl (salt wash). Then, cell lysates were analyzed by
Western blotting with an anti-gremlin antibody. Uniform loading of the samples was confirmed by incubation of the membrane with an
anti-tubulin antibody. B, Control and chlorate-treated HUVE cells were assessed for cell viability by the tetrazolium salt (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric assay according to standard procedures. C, Control and chlorate-
treated HUVE cells were stimulated for 10 minutes with phorbol myristate acetate (PMA) (10 ng/mL). Then, 50 g-aliquots of cell
lysates were analyzed by Western blotting with an anti-P-extracellular signaling–regulated kinase (P-ERK1/2) antibody. Uniform loading
of the gel was confirmed by incubation of the membrane with an anti-ERK2 antibody. D, Control and chlorate-treated HUVE cells were
allowed to adhere onto substrate-immobilized gelatin for 2 hours at room temperature, and attached cells were photographed under an
inverted microscope.
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Discussion
This is the first characterization of the interaction of gremlin
with heparin/HSPGs and of its role in mediating the angio-
genic response triggered by this noncanonical VEGFR2
ligand in ECs. Compared with other sulfated GAGs, heparin
(SO3/COO2.14)34 binds gremlin with high affinity
(Kd20 nmol/L). In HS (SO3/COO1.0),34 sulfate groups
are arranged in high-charge-density clusters intercalated with
low-charge-density regions,49 thus resulting in a lower
gremlin-binding activity. On the other hand, HS is a much
more effective gremlin interactor than dermatan sulfate,
chondroitin-4-sulfate, or chondroitin-6-sulfate, even though
they all share a similar charge, no significant binding being
observed with the nonsulfated hyaluronic acid and K5 poly-
saccharide. Also, similar to other heparin-binding angiogenic
proteins10,14 the affinity for gremlin is affected by the size of
the polysaccharide chain. Indeed, whereas low-MW heparin
tinzaparin binds gremlin with an affinity similar to unfrac-
tionated heparin, very-low-MW heparins showed a reduced
interaction, and a negligible binding was observed for 2.1-
kDa heparin. Interestingly, when compared with different
low-MW heparin preparations, tinzaparin has demonstrated
significant antiangiogenic and anticancer properties.44 Sev-
eral sets of experimental evidence demonstrate that physico-
chemical and biological properties of different low-MW
heparins are not alike.44 Even though additional studies are
required to fully characterize the interaction of gremlin with
different heparin preparations, our data clearly indicate that
the degree of sulfation, charge distribution, disaccharide
composition, and size are all important in determining the
capacity of sulfated GAGs to bind gremlin.
Previous observations had shown that fibroblast growth
factor-2 binds avidly to a pentasaccharide region in which
N-sulfate groups and a single 2-O-sulfate group are essential
for interaction. In contrast, N-sulfation and 6-O-sulfation are
crucial for VEGF-A165 binding, whereas 2-O-sulfate groups
are less essential.50 Our data demonstrate that selective 2-O-,
6-O-, or N-desulfation significantly reduces gremlin/heparin
interaction, indicating that they are all required for high
affinity binding. These findings support the hypothesis that
heparin-binding cytokines may bind sulfated GAGs in a
distinct manner. Even though specific factor binding se-
quences may be hidden in heparin because of its high degree
Figure 8. Heparan sulfate proteoglycans (HSPGs) mediate the
angiogenic activity of gremlin in endothelial cells (ECs). A and B,
Control (black bars) and chlorate-treated (open bars) human
umbilical vein endothelial (HUVE) cells were assessed for their
capacity to migrate in response to gremlin or phorbol myristate
acetate (PMA) in a modified Boyden chamber assay (A) or by
time-lapse videomicroscopy (B). C, Control (black bars) and
chlorate-treated (open bars) HUVE cells were incubated with
gremlin in the absence or in the presence of heparin (0.5 g/mL)
and assessed for their motility by time-lapse microscopy. D,
HUVE cell spheroids obtained from control, chlorate-treated, or
heparinase II–treated cells were embedded in fibrin gel and
incubated with gremlin. Formation of radially growing cell
sprouts was evaluated after 24 hours of incubation. E, Repre-
sentative microphotographs of control and chlorate-treated
HUVE cell spheroids stimulated with gremlin. In A to D, each
data are the meanSD of 2 or 3 independent experiments. Sig-
nificantly different from gremlin alone under the same experi-
mental conditions: *P0.004, **P0.001. FCS, fetal calf serum.
Figure 9. Sulfated K5 derivatives inhibit the angiogenic activity
of gremlin. A, Gremlin (20 nmol/L) was injected over a heparin-
coated BIAcore sensor chip in the presence of increasing con-
centrations of K5 (F), K5-NS (E), K5-OS(L) (f), K5-N,OS(L) (Œ),
K5-OS(H) (), or K5-N,OS(H) (‚), and the response (in reso-
nance units [RU]) was recorded at the end of the injection. B,
96-well plates coated with the extracellular domain of soluble-
vascular endothelial growth factor receptor-2 (sVEGFR2)D1–7
(200 ng/mL) were incubated with gremlin (50 ng/mL) in presence
of increasing concentrations of K5 (F) or K5-N,OS(H) (E). Then,
the formation of VEGFR2/gremlin complex was assessed by
incubation with an anti-gremlin antibody. C, Human umbilical
vein endothelial (HUVE) cell spheroids embedded in fibrin gel
were incubated with vehicle or gremlin in the absence (black
bars) or in the presence of K5 (open bars) or K5-N,OS(H) (gray
bars) (both at 10 ng/mL). Formation of radially growing cell
sprouts was evaluated after 24 hours of incubation. D, Alginate
pellets containing gremlin (100 ng/pellet) in the absence or in
the presence of K5 or K5-N,OS(H) (both at 1 g/pellet) were
implanted on chick embryo chorioallantoic membranes (10 eggs
per group). After 3 days, newly formed microvessels converging
vs the implant were counted. E, Representative images of cho-
rioallantoic membranes implanted with alginate pellets contain-
ing gremlin alone or gremlin added with K5-N,OS(H). Note the
numerous newly formed thin microvessels converging in a
spoke-wheel pattern vs the gremlin implant, significantly
reduced in the presence of K5-N,OS(H). Significantly different
from controls: **P0.001.
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of sulfation, the high heterogeneity in HS structure allows a
more refined tailoring of selective binding regions that may
influence the biological activity and bioavailability of
heparin/HS-binding growth factors.
In keeping with its heparin/HS binding capacity, gremlin
binds the surface of CHO-K1 cells but not of GAG-deficient
A745 CHO-K1 cells. Accordingly, gremlin binds HSPGs
exposed on the surface of ECs and deposited in the suben-
dothelial ECM, the binding being prevented by HS chain
digestion with heparinase II or by inhibition of HS chain
sulfation following EC treatment with chlorate. Similar to the
canonical heparin-binding VEGFR2 ligand VEGF-A165,
HSPG interaction appears to be essential for the binding of
gremlin to VEGFR2 and receptor activation in ECs. Indeed,
chlorate treatment or heparinase II digestion both hamper
gremlin/VEGFR2 interaction in HUVE cells. Accordingly,
VEGFR2 autophosphorylation triggered by gremlin is abol-
ished following HS digestion or undersulfation, yet is re-
stored by the addition of exogenous heparin. Similarly,
inhibition of HSPG interaction suppresses the ability of
gremlin to induce the activation of intracellular signaling
pathways in ECs, including ERK1/2 and p38 mitogen-acti-
vated protein kinase phosphorylation. Also, it inhibits EC
chemotactic migration, sprouting, and motility, all activities
that are mediated by a productive interaction of gremlin with
VEGFR2.29
NRP-1 is a transmembrane glycoprotein involved in the
interaction with a plethora of binding partners, including
class-3 semaphorin receptors, heparin-binding growth fac-
tors, and HSPGs.51 Also, NRP-1 core protein is modified with
either a single HS or condroitin sulfate chain depending on
the expressing cell type, thus increasing the complexity of
NRP-1 extracellular interactions.52 Several sets of experimen-
tal evidence indicate that the binding of mammalian heparin-
binding VEGF isoforms to HS and NRP-1 is interdependent.4
Gremlin does not contain the amino acid sequence CDKPRR
present in the VEGF-A165 carboxyl terminus and involved in
the interaction with b1b2 ectodomains of the NRP-1 core
protein.53 Even though we cannot rule out the possibility that
gremlin may bind the HS chain of NRP-1 in target cells, our
data indicate that, at variance with VEGF-A165, gremlin does
not interact with recombinant NRP-1 and does not trigger the
formation of a VEGFR2/NRP-1 complex in ECs. Also, the
structural bases for heparin/HS interaction may differ be-
tween VEGF isoforms and gremlin. Indeed, VEGFs bind HS
via a highly basic carboxyl-terminal region distinct from the
cystine-knot domain of the protein and encoded by alterna-
tively spliced exons.4 At variance, gremlin may interact with
heparin/HS via a linear basic patch along the third loop of its
cystine-knot domain, as suggested by homology modeling
prediction studies based on the cystine-knot BMP antagonist
sclerostin.31,32 Thus, gremlin differs from canonical heparin-
binding VEGFs in the ability to co-opt VEGFR2 coreceptors
and appears to exert a VEGFR2-dependent proangiogenic
activation of ECs with mechanisms that are, at least in part,
different from VEGFs. For instance, HSPGs contribute to
VEGF-triggered angiogenesis by a mechanism dependent on
the modulation of 61 integrin expression on the EC
surface.54 At variance with VEGF-A, gremlin does not
upregulate the expression of 6 integrin in ECs (data not
shown), further underscoring the different mechanism of
action of the 2 angiogenic factors.
Chemical or enzymatic modifications of the E. coli capsular
K5 polysaccharide allow the production of “biotechnological”
semisynthetic heparin/HS-like compounds with selected chem-
ical features, with potential implications in the therapy of various
human pathologies, including thromboembolic diseases, viral
infection, and neoplasia.16,55 Here we evaluated the gremlin-
binding capacity of a series of specific N-, O-, or N,O-sulfated
nonanticoagulant K5 derivatives.33 Among the compounds
tested, highly sulfated K5-N,OS(H) binds gremlin with higher
affinity compared with the corresponding derivative K5-OS(H)
devoid of sulfate group in the N position but bearing an identical
total negative charge (SO3/COO of 3.8 for both com-
pounds33). K5-OS(H) consists of the virtually homogeneous
repeat of GlcA2,3SO3-GlcNAc3,6SO3 disaccharide units,
whereas most of K5-N,OS(H) sequences are represented by
GlcA2,3SO3-GlcNSO3,6SO3 disaccharide units.33 Our
data indicate that the requirement for N-sulfation present in
K5-N,OS(H) cannot be fully overcome by the high density
charge present in the highly O-sulfated K5-OS(H). Similarly,
low sulfated K5-N,OS(L) binds gremlin more efficiently than
Figure 10. K5-N,OS(H) inhibits the angiogenic activity of
gremlin-overexpressing human pancreatic carcinoma-1
(PANC-1) cells. A, Conditioned media from PANC-1-green fluo-
rescent protein (GFP) and PANC-1-gremlin cells grown for 48
hours in serum-free Dulbecco’s modified Eagle medium (DMEM)
were analyzed by Western blotting with an anti-gremlin anti-
body. B, Human umbilical vein endothelial (HUVE) cells were
stimulated for 15 minutes with the conditioned medium from
PANC-1-GFP or PANC-1-gremlin cells. Then, 50 g-aliquots of
cell extracts were analyzed by Western blotting with an anti-P-
vascular endothelial growth factor receptor-2 (VEGFR2) anti-
body. Uniform loading of the gel was confirmed by incubation of
the membrane with an anti-VEGFR2 antibody. PANC-1-gremlin
cells released gremlin in a bioactive form, as demonstrated by
the capacity of their conditioned medium to induce VEGFR2
phosphorylation in HUVE cells. C and D, Human umbilical artery
rings (4 rings per group) were embedded in fibrin gel and stimu-
lated with the conditioned medium from PANC-1-GFP or PANC-
1-gremlin cells in the absence (black bars) or in the presence of
K5 (open bars) or K5-N,OS(H) (gray bars) (both at 100 ng/mL).
After 6 days, endothelial cell (EC) sprouts were counted (C) and
photographed under an inverted microscope at a 200 magnifi-
cation (D). Significantly different from controls: *P0.03.
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K5-OS(L), even though both compounds have a SO3/COO
value of 1.7.33 On the other hand, K5-NS devoid of sulfate
groups in O positions (SO3/COO of 1.0) does not have a
significant interaction with gremlin. Thus, in agreement with
the results obtained with selectively desulfated heparins, N-
and O-sulfate groups are required for gremlin interaction with
sulfated K5 derivatives.
Gremlin exerts both BMP-dependent and BMP-
independent functions in different physiopathological condi-
tions by inhibiting BMP-mediated TGF- receptor activation
or by a direct activation of VEGFR2 signaling, respectively.
In this respect, it is interesting to note that a complex, not yet
fully elucidated cross-talk may exist among TGF-/BMP,
VEGFR2, and canonical and noncanonical Wingless (Wnt)
signaling pathways during angiogenesis,56 making unpredict-
able the impact of the modulation of a single agonist/antag-
onist on the neovascularization process in different patholog-
ical conditions. Here, we demonstrate that K5-N,OS(H) is a
potent antagonist of gremlin, inhibiting VEGFR2 interaction
and angiogenic activity in vitro and in vivo. Also, K5-
N,OS(H) may prevent gremlin-driven tumor neovasculariza-
tion, as indicated by its capacity to suppress the angiogenic
potential of gremlin-overexpressing human tumor PANC-1
cells in an ex vivo human artery ring assay. Previous
observations had shown the ability of K5-N,OS(H) to inhibit
the angiogenic activity of the heparin-binding molecules
fibroblast growth factor-2 and HIV-1 Tat protein16 and to
reduce tumor invasion by hampering heparanase activity16
and tumor metastasis.57 Thus, K5-N,OS(H) may represent the
basis for the design of novel nonanticoagulant biotechnolog-
ical heparins endowed with a multitarget antineoplastic action
by interacting with different angiogenic growth factors and
limiting tumor cell invasion and metastasis. Also, preclinical
and clinical studies identify gremlin as a potential therapeutic
target in human fibrotic diseases characterized by alterations
of TGF-/BMP signaling and vascular defects in different
organs as liver,58 kidney,24 and lung.23 Given the role of
gremlin in physiological development and different patholog-
ical conditions, additional preclinical in vivo studies will be
required to define the therapeutic capability and possible side
effects of gremlin antagonists, including K5-N,OS(H) and its
derivatives.
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